2' fana modified foxp3 antisense oligonucleotides and methods of use thereof
AssigneesAUM LifeTech, Inc, The Children's Hospital of Philadelphia
InventorsVeenu Aishwarya, Wayne W. Hancock
Life of this patent
Estimating the term…
Abstract
The present invention is directed to hybrid chimera antisense oligonucleotides including deoxyribonucleotide and 2′-deoxy-2′-fluoro-β-D-arabinonucleotide which binds to a Foxp3 mRNA, and to methods of use thereof. The methods include the use for reducing expression level of Foxp3 gene, increasing anti-tumor activity, and treating cancer in a subject.
Claims21
1-38. (canceled)
A modified antisense oligonucleotide (AON) comprising at least one 2′-deoxy-2′-fluoro-β-D-arabinonucleotide (2′-FANA modified nucleotide), wherein the AON binds to a Foxp3 mRNA.
A pharmaceutical composition comprising a modified antisense oligonucleotide (AON) comprising at least one 2′-deoxy-2′-fluoro-β-D-arabinonucleotide (2′-FANA modified nucleotide) and a pharmaceutically acceptable carrier, wherein the AON binds to a Foxp3 mRNA.
A method of treating cancer in a subject in need thereof comprising administering to the subject at least one antisense oligonucleotide (AON), wherein the AON binds to a Foxp3 mRNA, and wherein the AON comprises at least one 2′-deoxy-2′-fluoro-β-D-arabinonucleotide (2′-FANA modified nucleotide), thereby treating the cancer.
Dependencies are inferred from the claim text.